• Je něco špatně v tomto záznamu ?

In vitro and in vivo study of 221Fr and 213Bi progeny release from the 225Ac-labelled TiO2 nanoparticles

M. Sakmár, J. Kozempel, J. Kučka, T. Janská, M. Štíbr, L. Ondrák, K. Ondrák Fialová, M. Vlk, L. Šefc, F. Bruchertseifer, A. Morgenstern

. 2025 ; 140-141 (-) : 108973. [pub] 20241113

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010467

BACKGROUND: Targeted alpha therapy (TAT) is an effective option for cancer treatment. To maximize its efficacy and minimize side effects, carriers must deliver radionuclides to target tissues. Most of the nuclides used in TAT decay via the alpha cascade, producing several radioactive daughter nuclei with sufficient energy to escape from the original carrier. Therefore, studying these daughter atoms is crucial in the search for new carriers. Nanoparticles have potential as carriers due to their structure, which can prevent the escape of daughter atoms and reduce radiation exposure to non-target tissues. This work focuses on determining the released activity of 221Fr and 213Bi resulting from the decay of 225Ac labelled TiO2 nanoparticles. RESULTS: Labelling of TiO2 nanoparticles has shown high sorption rates of 225Ac and its progeny, 221Fr and 213Bi, with over 92 % of activities sorbed on the nanoparticle surface for all measured radionuclides. However, in the quasi-dynamic in vitro system, the released activity of 221Fr and 213Bi is strongly dependent on the nanoparticles concentration, ranging from 15 % for a concentration of 1 mg/mL to approximately 50 % for a nanoparticle concentration of 10 μg/mL in saline solution. The released activities of 213Bi were lower, with a maximum value of around 20 % for concentrations of 0.05, 0.025, and 0.01 mg/mL. The leakage of 225Ac and its progeny was tested in various biological matrices. Minimal released activity was measured in saline at around 10 % after 48 h, while the maximum activity was measured in blood serum and plasma at 20 %. The amount of 225Ac released into the media was minimal (<3 %). The in vitro results were confirmed in a healthy mouse model. The difference in %ID/g was clearly visible immediately after dissection and again after 6 h when 213Bi reached equilibrium with 225Ac. CONCLUSION: The study verified the potential release of 225Ac progeny from the labelled TiO2 nanoparticles. Experiments were performed to determine the dependence of released activity on nanoparticle concentration and the biological environment. The results demonstrated the high stability of the prepared 225Ac@TiO2 NPs and the potential release of progeny over time. In vivo studies confirmed our hypothesis. The data obtained suggest that the daughter atoms can escape from the original carrier and follow their own biological pathways in the organism.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010467
003      
CZ-PrNML
005      
20250429135006.0
007      
ta
008      
250415e20241113xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.nucmedbio.2024.108973 $2 doi
035    __
$a (PubMed)39579560
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sakmár, Michal $u Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, 11519 Prague 1, Czech Republic; Institute of Nuclear Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 5, 12808 Prague, Czech Republic
245    10
$a In vitro and in vivo study of 221Fr and 213Bi progeny release from the 225Ac-labelled TiO2 nanoparticles / $c M. Sakmár, J. Kozempel, J. Kučka, T. Janská, M. Štíbr, L. Ondrák, K. Ondrák Fialová, M. Vlk, L. Šefc, F. Bruchertseifer, A. Morgenstern
520    9_
$a BACKGROUND: Targeted alpha therapy (TAT) is an effective option for cancer treatment. To maximize its efficacy and minimize side effects, carriers must deliver radionuclides to target tissues. Most of the nuclides used in TAT decay via the alpha cascade, producing several radioactive daughter nuclei with sufficient energy to escape from the original carrier. Therefore, studying these daughter atoms is crucial in the search for new carriers. Nanoparticles have potential as carriers due to their structure, which can prevent the escape of daughter atoms and reduce radiation exposure to non-target tissues. This work focuses on determining the released activity of 221Fr and 213Bi resulting from the decay of 225Ac labelled TiO2 nanoparticles. RESULTS: Labelling of TiO2 nanoparticles has shown high sorption rates of 225Ac and its progeny, 221Fr and 213Bi, with over 92 % of activities sorbed on the nanoparticle surface for all measured radionuclides. However, in the quasi-dynamic in vitro system, the released activity of 221Fr and 213Bi is strongly dependent on the nanoparticles concentration, ranging from 15 % for a concentration of 1 mg/mL to approximately 50 % for a nanoparticle concentration of 10 μg/mL in saline solution. The released activities of 213Bi were lower, with a maximum value of around 20 % for concentrations of 0.05, 0.025, and 0.01 mg/mL. The leakage of 225Ac and its progeny was tested in various biological matrices. Minimal released activity was measured in saline at around 10 % after 48 h, while the maximum activity was measured in blood serum and plasma at 20 %. The amount of 225Ac released into the media was minimal (<3 %). The in vitro results were confirmed in a healthy mouse model. The difference in %ID/g was clearly visible immediately after dissection and again after 6 h when 213Bi reached equilibrium with 225Ac. CONCLUSION: The study verified the potential release of 225Ac progeny from the labelled TiO2 nanoparticles. Experiments were performed to determine the dependence of released activity on nanoparticle concentration and the biological environment. The results demonstrated the high stability of the prepared 225Ac@TiO2 NPs and the potential release of progeny over time. In vivo studies confirmed our hypothesis. The data obtained suggest that the daughter atoms can escape from the original carrier and follow their own biological pathways in the organism.
650    12
$a titan $x chemie $7 D014025
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    12
$a aktinium $x chemie $7 D000186
650    12
$a nanočástice $x chemie $7 D053758
650    _2
$a izotopové značení $7 D007553
650    _2
$a radionuklidy $x chemie $7 D011868
650    _2
$a tkáňová distribuce $7 D014018
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kozempel, Ján $u Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, 11519 Prague 1, Czech Republic. Electronic address: jan.kozempel@fjfi.cvut.cz
700    1_
$a Kučka, Jan $u Czech Academy of Sciences, Institute of Macromolecular Chemistry, Heyrovského náměstí 1888-2, 16000 Prague 6, Czech Republic
700    1_
$a Janská, Tereza $u Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, 11519 Prague 1, Czech Republic
700    1_
$a Štíbr, Matěj $u Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, 11519 Prague 1, Czech Republic
700    1_
$a Ondrák, Lukáš $u Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, 11519 Prague 1, Czech Republic
700    1_
$a Ondrák Fialová, Kateřina $u Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, 11519 Prague 1, Czech Republic
700    1_
$a Vlk, Martin $u Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, 11519 Prague 1, Czech Republic
700    1_
$a Šefc, Luděk $u Charles University in Prague, 1(st) Faculty of Medicine, Center for Advanced Preclinical Imaging (CAPI), Salmovská 3, 12000 Prague 2, Czech Republic
700    1_
$a Bruchertseifer, Frank $u Joint Research Centre, European Commission, Karlsruhe, Germany
700    1_
$a Morgenstern, Alfred $u Joint Research Centre, European Commission, Karlsruhe, Germany
773    0_
$w MED00008576 $t Nuclear medicine and biology $x 1872-9614 $g Roč. 140-141 (20241113), s. 108973
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39579560 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135001 $b ABA008
999    __
$a ok $b bmc $g 2311678 $s 1247548
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 140-141 $c - $d 108973 $e 20241113 $i 1872-9614 $m Nuclear medicine and biology $n Nucl Med Biol $x MED00008576
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...